Hims & Hers Health (NYSE: HIMS) to acquire YourBio Health to add patented, pain-free TAP and HALO blood sampling technology to its wellness platform The acquisition will integrate virtually painless microneedle blood collection into a broader direct‑to‑consumer health platform, enabling fast, high‑quality capillary sampling outside traditional clinics. Protected microtechnology around device design, sample handling, and integration supports future test expansion, while incoming scientific and executive leaders will steer development of more user‑friendly diagnostics after the all‑cash deal closes. (Link)
Overjet acquires Toledo AI startup DentalBee to combine voice-driven documentation with dental imaging in a unified clinical intelligence platform The transaction pairs real-time voice capture of periodontal measurements, notes, and referral details with AI analysis of X‑rays to create fully structured dental records while easing documentation burden for clinicians. It also underscores Northwest Ohio’s emergence as an AI hub, with regional economic development groups credited for helping the startup reach acquisition. (Link)
Joi + Blokes acquires HerMD to build a nationwide virtual women’s health platform for menopause, sexual health, and hormonal care The merger will expand access to longer virtual consults with hormone and menopause specialists, broader treatment options, and preventive lab support in every state, while adding research participation opportunities. HerMD’s education-first approach will drive new national learning initiatives as the combined platform works to deliver more consistent, empathetic, evidence-based care to underserved midlife women. (Link)
Lightbeam Health Solutions acquires Syntax Health to integrate value-based contracting and actuarial modelling into its AI-enabled population health platform The acquisition adds a contract‑modelling engine and actuarial talent into a broader value‑based care operating system, allowing payers and providers to rapidly simulate deals, align on assumptions, and project financial results with more confidence. By tying benchmarking and forecasting directly to contract design, the combined platform aims to reduce administrative complexity and refocus attention on population outcomes. (Link)
Avandra Health acquires DatCard Systems and Sorna Corporation to build a unified global medical imaging and clinical data platform for patient care and research The enlarged platform will connect distribution tools already embedded at thousands of sites with a federated, de‑identified imaging network, making it easier for hospitals to share studies and for life sciences partners to tap high‑value data. By investing in upgrades and support while preserving existing brands, the organization aims to unlock siloed imaging for both care and research. (Link)
Ciba Health partners with Quikcard to launch personalized, prevention‑first metabolic and chronic care programs for Canadians The partnership brings structured 12‑month programs with dietitian and health‑coach support, personalized plans, and continuous tracking to help members address metabolic risk and chronic conditions through lifestyle change rather than medication alone. Validated outcomes include meaningful HbA1c drops, sharply reduced overall drug use and costs, and GLP‑1 Step Down participants lowering GLP‑1 dependence while losing weight over six months. (Link)
XRHealth acquires Innerworld to build an immersive, stepped-care XR platform for mental health and rehabilitation The combined platform will pair always‑on, community‑based mental health support—via live events, facilitator‑led groups, and global peer interaction—with existing VR/AR treatments for pain, rehab, PTSD, stress, addiction, and OCD. By adding Innerworld’s founder as chief clinical officer and building on prior XR acquisitions, the company is constructing a stepped‑care, AI‑enhanced XR ecosystem spanning self‑help to clinician‑guided therapy. (Link)
Cerbo acquires OptiMantra, via its financial sponsors Search Fund Partners, Applied Equity Partners, Manifestations Capital, Hunter Search Capital, Endurance Search Partners, and Red Forest Capital to build AI-powered practice platform for specialty and integrative care The merger creates a single EMR and practice‑management platform for integrative, functional, direct primary care, concierge, behavioral health, and IV/injectable practices, targeting the operational needs of membership‑ and cash‑pay models. Backed by multiple financial sponsors, the combined team will co‑develop AI‑enabled workflows, CRM-driven growth tools, and upgraded payment capabilities while keeping founders engaged and a customer‑first culture intact. (Link)
BriteLife Recovery acquires Summit Behavioral Health to add intensive outpatient services to its East Coast addiction treatment network The deal extends care into flexible day and evening intensive outpatient programming at the Princeton Junction site, supported by transportation, alumni services, family recovery programming, and enhanced staff training. BriteLife’s broader network across several East Coast states, plus insurance acceptance and scholarships, is intended to make trauma‑informed, relationship‑centered treatment more accessible. (Link)
CQ Medical acquires Bionix Radiation Therapy business unit to expand global radiotherapy positioning and marking portfolio The acquisition brings additional radiotherapy accessories and a seasoned sales team under the same umbrella, broadening an existing suite of positioning, immobilization, and image‑guided treatment devices used in oncology. CQ Medical plans to absorb the new product lines into its current manufacturing footprint while Bionix redirects attention and investment to its remaining ambulatory care portfolio. (Link)
Natera (NASD: NTRA) acquires Foresight Diagnostics in up to $450 million deal to expand minimal residual disease cancer testing portfolio The transaction adds ultra‑sensitive PhasED‑Seq assays that can detect lymphoma relapse at very low circulating tumour DNA levels long before standard imaging, alongside a CLIA‑registered lab and lymphoma expertise that deepen the existing MRD offering. It follows settlement of past IP disputes and comes amid strong cancer testing growth but continued net losses. (Link)
Paradigm Health raises $78 million Series B from ARCH Venture Partners, DFJ Growth, F-Prime, General Catalyst, GV, Lux Capital, Mubadala Capital, and American Cancer Society’s BrightEdge Fund to expand AI-enabled clinical trial infrastructure The platform links biopharma sponsors with 166 provider organizations and 2,100 care sites across 45 states. Automated matching and site-feasibility tools let health systems enrol up to four times faster and reduce clinician burden, while a new design service embeds interventional and pragmatic trials directly into routine workflows and expands into neuroscience, cardiovascular, and metabolic research. (Link)
Artera raises $65 million from Lead Edge Capital, Jackson Square Ventures, Health Velocity Capital, Heritage Medical Systems, and Summation Health Ventures to scale agentic AI for patient communication The company is using a decade of real‑world communication data to train AI that automates routine scheduling, intake, billing, and messaging across more than 1,000 provider organizations and 2 billion yearly interactions. Its “flow agents” already handle most exchanges without staff, while co‑pilot tools summarize, translate, and surface priority outreach, saving substantial administrative time. (Link)
Curi Bio raises $10 million Series B led by DreamCIS to scale human iPSC-based preclinical platforms and advanced functional data analysis for drug discovery Curi Bio is expanding a platform that uses high‑purity human iPSC‑derived cells, tissue‑specific 3D biosystems, and rich functional data to predict human drug responses more accurately than animal or 2D models. These assays guide candidate selection and IND decisions across multiple diseases, while partner DreamCIS contributes clinical research and regulatory expertise to boost trial success. (Link)
Lyric Bio, Inc. raises $6.6 million seed round led by The Venture Collective, with Black Diamond Ventures, Draper Associates, Lucas Venture Group, Meiji Seika Pharma, SOSV, and others to advance donor‑derived therapeutics biomanufacturing Lyric Bio is building ultra‑high‑density 3D bioreactors that mimic human tissue to manufacture donor‑derived therapies at scale, starting with IVIg and SCIg in a $20 billion market. By targeting up to 100x efficiency gains, the team aims to slash costs, cut reliance on human donors, and deliver more consistent, accessible immunoglobulin products. (Link)
